Activist Group with 31.5% Voting Power Challenges Genenta Science's Governance and Strategic Direction
GNTA is trading near its 52-week low of $0.59 (9.7% above the low).
Summary
A newly formed activist shareholder group, holding 23.0% of outstanding shares and 31.5% of voting power, has filed a Schedule 13D to challenge Genenta Science's corporate governance and strategic direction, including recent amendments to its Articles of Association.
Key Events · Ownership and Investor Activity · GNTA
-
Activist Group Formed
A group of 11 individuals and entities has formed an activist shareholder group, entering into a Shareholders' and Joint Filing Agreement on May 4, 2026.
-
Significant Ownership Stake
The group collectively holds 5,433,910 Ordinary Shares and American Depository Shares (ADS), representing approximately 23.0% of the Issuer's outstanding shares and 31.5% of the total voting power.
-
Challenges Corporate Governance
The group intends to promote stability, monitor board actions, and oppose recent amendments to the company's Articles of Association, specifically a multiple voting mechanism and a 'Golden Power' corporate purpose clause.
-
Legal Proceedings Underway
A subset of the reporting persons has already challenged the multiple voting mechanism (May 2, 2024) and the 'Golden Power' amendment (October 29, 2025) in the Court of Milan, with proceedings pending.
Analysis · GNTA · Life Sciences
This Schedule 13D filing reveals the formation of a significant activist shareholder group that intends to actively influence Genenta Science's corporate governance. The group, comprising individuals and entities, collectively holds a substantial 23.0% of the company's outstanding shares and 31.5% of its total voting power, a highly material stake for a company of this size. Their stated purpose includes promoting stability, monitoring board actions, and opposing recent amendments to the company's Articles of Association, specifically regarding a multiple voting mechanism and a "Golden Power" corporate purpose clause. The fact that some members have already initiated legal proceedings against these resolutions underscores the contentious nature of this development. Investors should anticipate potential proxy battles, ongoing legal disputes, and significant changes to the company's board and strategic focus as this activist campaign unfolds. The group's intention to present a joint slate for board elections signals a direct challenge to current management and board control.
At the time of this filing, GNTA was trading at $0.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.2M. The 52-week trading range was $0.59 to $10.00. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.